In this Product Explainer, Cardiologist Prof Andrew Sindone explains the role of dapagliflozin in cardiorenal protection in patients with heart failure, chronic kidney disease and/or type 2 diabetes.
Inappropriate DOAC dosing is a common problem- recognise which patients require reduced dosage, what GPs can do to optimise the dosage in view of the specific clinical characteristics of each patient.